AVA-322/AVA-323
AVA-322 and AVA-323 are next-generation gene therapy product candidates, which are being evaluated as treatments for color vision deficiency (CVD), commonly known as red-green color blindness. CVD is one of the most common genetic diseases, affecting over 10 million people in the U.S. alone, for which there currently are no available treatment options.1
AVA-322 carries the gene for L-opsin and is being developed for the treatment of protan defects, while AVA-323 carries the gene for M-opsin and is being developed for the treatment of deutan defects. Both drug candidates utilize Avalanche’s breakthrough non-surgical intravitreal injection method to deliver genes directly to cone cells at the back of the eye.
1Sharpe LT, Stockman A, Jagle H, Nathans J. Opsin genes, photopigments, color vision and color blindness. In: Gegenfurtner KR, Sharpe LT (eds.) Color Vision. Cambridge UP: Cambridge, 1999
